OncLive TV

John Mascarenhas, MD, outlines the ongoing phase 3 IMpact-MF trial, evaluating imetelstat in relapsed/refractory myelofibrosis.

Morana Vojnic, MD, MBA, discusses vorasidenib in grade 2 IDH1/2-mutated glioma.

Jonathan H. Sherman, MD, FAANS, FCNS, FACS, discusses notable advances in the surgical management of patients with brain tumors.

Martin Dreyling, MD, PhD, discusses the use of BTK inhibitors in frontline mantle cell lymphoma.

Jane L. Meisel, MD, FASCO, discusses the mechanism of action of palazestrant in ER+, HER2– advanced/metastatic breast cancer.

Paolo Ghia, MD, provided insights into the significance of updated data from the final analysis of the phase 2 CAPTIVATE study in CLL/SLL.

Janice M. Mehnert, MD, discusses the ongoing investigation of sarilumab plus ipilimumab, nivolumab, and relatlimab in unresectable stage III/IV melanoma.

Cyrus M. Khan, MD, discusses the key BTK inhibitor updates for the treatment of patients with relapsed/refractory CLL from the 2025 ASCO Annual Meeting.

John H. Strickler, MD, details the impetus for evaluating the novel c-Met–directed ADC Temab-A in refractory metastatic colorectal cancer.

Paul Nathan, MBBS, PhD, MRCP, describes the mechanism of action of roginolisib and its ongoing evaluation in metastatic uveal melanoma.

J. Thaddeus Beck, MD, FACP, discusses the FDA approval of subcutaneous pembrolizumab and berahyaluronidase for use across all adult and solid-tumor indications.

Danny Rischin, MD, discusses key DFS data from the phase 3 C-POST trial of adjuvant cemiplimab vs placebo in patients with high-risk CSCC.

Oliver Van Oekelen, MD, PhD, discusses how S100A8/A9 in promotes T-cell exhaustion and limits responses to bispecific antibody therapy in multiple myeloma.

Kohei Shitara, MD, discusses efficacy data from a trial of the CAR T-cell therapy satri-cel in advanced gastric/ GEJ adenocarcinoma and pancreatic cancer.

Marc S. Raab, MD, discusses teclistamab for the treatment of patients with newly diagnosed multiple myeloma.

Efrat Dotan, MD, discusses gemcitabine and nab-paclitaxel in treatment-naive, older patients with pancreatic cancer.

Jennifer A. Woyach, MD, discusses when to initiate subsequent therapy in patients with CLL.

Eric Nadler, MD, MPP, discusses the inherent complexity of diagnosing sarcomas.

Mats Jerkeman, MD, discusses essential symptoms of MCL warranting referral for earlier diagnosis.

Dana M. Chase, MD, expands on the importance of endometrial cancer awareness month, which is observed annually in September.

Asad Dean, MD, discusses the role of pirtobrutinib in second-line CLL.

Brian Slomovitz, MD, discusses the importance of education, prevention, and research in the context of gynecologic cancer awareness month.

Sara M. Tolaney, MD, MPH, discusses the potential role of Sac-TMT with/without pembrolizumab in HR+, HER2– breast cancer.

Xavier Leleu, MD, PhD, discusses the role of subcutaneous isatuximab delivered via an on-body delivery system in patients with relapsed/refractory multiple myeloma.

Larry Anderson, MD, PhD, discusses updated efficacy and safety findings of subcutaneous daratumumab plus lenalidomide in newly diagnosed multiple myeloma following autologous stem cell transplant.

Alberto Farolfi, MD, PhD, discusses bevacizumab plus SOC in advanced cervical cancer and no contraindications for antiangiogenic agents.

Sharlene Gill, BScPharm, MD, MPH, MBA, FRCPC, discusses patient experiences and involvement in decision-making in CRC.

Omar Nadeem, MD, discusses updated data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel in relapsed/refractory multiple myeloma.

Paula Rodriguez-Otero, MD, discusses safety and efficacy findings with linvoseltamab, a bispecific antibody targeting BCMA, in patients with high-risk smoldering multiple myeloma.

Greg Durm, MD, discusses factors that influence his decision to utilize perioperative treatment in patients with early-stage NSCLC.